Artia Global Partners LP Takes Position in Dianthus Therapeutics, Inc. $DNTH

Artia Global Partners LP bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 162,990 shares of the company's stock, valued at approximately $15,888,000. Dianthus Therapeutics makes up about 2.9% of Artia Global Partners LP's investment portfolio, making the stock its 11th biggest holding. Artia Global Partners LP owned 0.30% of Dianthus Therapeutics at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of DNTH. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth $27,000. First Horizon Corp purchased a new position in Dianthus Therapeutics in the first quarter worth about $32,000. Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics in the fourth quarter worth about $40,000. EFG International AG purchased a new position in Dianthus Therapeutics in the second quarter worth about $49,000. Finally, Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics during the third quarter worth approximately $64,000. Institutional investors own 47.53% of the company's stock.

Analyst Upgrades and Downgrades

DNTH has been the topic of several analyst reports. TD Cowen reissued a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wolfe Research restated an "outperform" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. HC Wainwright lifted their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Wedbush boosted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $124.27.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of the company's stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the transaction, the chief executive officer directly owned 65,292 shares in the company, valued at $7,058,718.12. This represents a 71.77% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is owned by company insiders.

Dianthus Therapeutics Stock Performance

DNTH opened at $110.76 on Thursday. The stock has a market cap of $6.05 billion, a price-to-earnings ratio of -26.69 and a beta of 1.22. The stock's 50 day moving average price is $102.55 and its 200-day moving average price is $86.52. Dianthus Therapeutics, Inc. has a one year low of $22.81 and a one year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source